LOS ANGELES, CA / ACCESSWIRE / September 28, 2016 / Lundin Law PC (the "Firm") announces the filing of a class action lawsuit against Keryx Biopharmaceuticals Inc. ("Keryx" or the "Company") (Nasdaq: KERX) concerning possible violations of federal securities laws between February 25, 2016 and August 1, 2016 (the "Class Period"). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the Firm in advance of the October 3, 2016 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The complaint alleges that throughout the Class Period, Keryx made false and misleading statements and/or failed to disclose: that the Company was experiencing production-related difficulties in converting API to finished drug product; that the issue was resulting in decreased production yields of finished drug product; that the Company exhausted its reserve of finished drug product; and as a result of the above, Keryx's statements about its business, operations and prospects were false and misleading and/or lacked a reasonable basis at all relevant times. When the true details emerged to the public, the stock price of Keryx decreased, thus causing investors harm.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact:
Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/
SOURCE: Lundin Law PC
ReleaseID: 446165
